IL-1 and IL-6 antagonists have proven efficacy in most SJIA patients who would in the past have developed long-lasting inflammation and fail to adequately respond to methotrexate or other biologics such as TNF alpha antagonists. This evidence concerns the gene TNF and systemic-onset juvenile idiopathic arthritis.